Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Liposomal Drug Delivery Devices Market Value Growth And Long-Term Outlook
The liposomal drug delivery devices market size has experienced significant growth in recent years. It is projected to expand from $5.34 billion in 2025 to $6.01 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.4%. This historical growth can be attributed to advancements in nanotechnology-based drug delivery, increasing cancer prevalence, the expansion of injectable drug formulations, the rising use of liposomal antifungal therapies, and growing pharmaceutical research investments.
The liposomal drug delivery devices market size is anticipated to experience substantial expansion over the upcoming years. It is projected to reach $9.49 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 12.1%. This growth during the forecast period stems from factors such as a heightened demand for targeted cancer therapies, the widening of personalized medicine strategies, increased uptake of advanced drug delivery systems, growing investments in biologics and vaccines, and an intensified focus on reducing drug toxicity. Key trends expected within this period encompass the growing integration of targeted drug delivery systems, a rise in the utilization of pegylated liposomal formulations, their expanding use in oncology treatments, the broader development of liposomal vaccines and antifungals, and a stronger emphasis on controlled drug release mechanisms.
Get A Free Sample Report With In-Depth Market Insights:
Liposomal Drug Delivery Devices Market Growth Factors Behind Sustained Expansion
The increasing incidence of cancer globally is projected to drive the expansion of the liposomal drug delivery devices market moving forward. Cancer, a broad category of illnesses marked by the uncontrolled proliferation and dissemination of abnormal cells, is becoming more prevalent due to the combined effects of an aging population, environmental risk factors, and evolving lifestyles. As the prevalence of cancer grows, there is a heightened need for advanced, targeted treatments, such as liposomal formulations, which can optimize drug delivery, minimize systemic toxicity, and boost treatment effectiveness. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported an estimated 20 million new cancer cases in 2022, with projections indicating this number will climb to 35 million by 2050, representing a 77% increase. Consequently, the escalating worldwide burden of cancer is fueling the growth of the liposomal drug delivery devices market.
Liposomal Drug Delivery Devices Market Segment Outlook: Which Categories Are Growing Fastest?
The liposomal drug delivery devices market covered in this report is segmented –
1) By Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types
2) By Application: Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy
3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Other End Users
Subsegments:
1) By Liposomal Doxorubicin: Conventional Liposomal Doxorubicin, PEGylated Liposomal Doxorubicin
2) By Liposomal Paclitaxel: Conventional Liposomal Paclitaxel, PEGylated Liposomal Paclitaxel
3) By Liposomal Amphotericin B: Conventional Liposomal Amphotericin B, PEGylated Liposomal Amphotericin B
4) By Other Types: Liposomal Irinotecan, Liposomal Vincristine, Liposomal Cytarabine
Liposomal Drug Delivery Devices Market Industry Trends Fueling Future Revenue Growth
Leading companies in the liposomal drug delivery sector are unveiling innovative products, such as hydrochloride liposome injection, to secure a competitive advantage. Researchers are actively developing liposomal nanostructures aimed at improving patient compliance by enabling less frequent doses while maintaining therapeutic efficacy. For instance, in August 2024, Lupin Ltd., an India-based pharmaceutical firm, launched Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL). As of June 2024, the Doxorubicin Hydrochloride Liposome Injection had an estimated annual sales figure of approximately USD 40.9 million in the U.S. market. This strategically positions Lupin within the oncology segment, expanding its product line to include this crucial cancer treatment option. Lupin’s dedication to enhancing patient health outcomes is evident with this release, as it aims to provide effective treatment alternatives amidst a competitive pharmaceutical landscape.
Liposomal Drug Delivery Devices Market Competitive Overview And Top Companies
Major companies operating in the liposomal drug delivery devices market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Gilead Sciences Inc., Ipsen SA, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd., Nanomerics Ltd., Luye Pharma Group Ltd., Leadiant Biosciences Inc., Pacira Biosciences Inc., Nippon Kayaku Co. Ltd., Celsion Corporation, Acrotech Biopharma Inc., Aphios Pharma LLC, CytImmune Sciences Inc., NanoSphere Health Sciences Inc., Cel-Sci Corporation, Lipoid GmbH, Liposome Company Inc., Liposome Research Days Corporation, Taiwan Liposome Company
View The Full Liposomal Drug Delivery Devices Market Report:
Liposomal Drug Delivery Devices Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the liposomal drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.